# MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma

> **NCT02764281** · NA · COMPLETED · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 53 (actual)

## Conditions studied

- Extranodal NK-T-Cell Lymphoma, Nasal Type

## Interventions

- **DRUG:** MEDA
- **PROCEDURE:** Auto-HSCT

## Key facts

- **NCT ID:** NCT02764281
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2020-02
- **Final completion:** 2020-02
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2020-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764281, "MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02764281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*